Gina Life is a technology company.
Gina Life has raised $3.0M across 1 funding round.
Gina Life has raised $3.0M in total across 1 funding round.
Gina Life has raised $3.0M in total across 1 funding round.
Gina Life's investors include Pitango Venture Capital.
Gina Life is an Israel-based femtech startup founded in 2015, developing an AI-powered platform for early detection of women's health diseases, primarily ovarian cancer, through analysis of vaginal discharge biomarkers.[1][2][3] The company creates a simple test pad or home-testing kit that captures secretions, uses machine learning to identify key proteins, and generates personalized results via a mobile app, targeting at-risk women, those with ovarian pathologies, and the general population to address late diagnosis issues.[1][2][4] It serves women globally, solving the problem of undetected diseases like ovarian cancer, endometrial cancer, and endometriosis by enabling affordable, non-invasive screening that reduces male bias in diagnostics and hospital burdens.[2][3][5] As of 2023, Gina Life (now Nevia Bio) completed a $3.1M seed round, conducted trials with over 1,000 participants, and initiated US proof-of-concept studies, earning awards like Frost & Sullivan's 2022 Israeli Technology Innovation Leadership.[2][4][8]
Gina Life emerged from personal tragedy and scientific curiosity. Dr. Inbal Zafir-Lavie, CEO with a PhD in Immunology from the Technion, lost her sister to late-diagnosed ovarian cancer, inspiring her to co-found the company in 2015 with Dr. Shlomit Yehudai-Reshef, a molecular biologist and CSO who directs Rambam Health Care Campus's Clinical Research Institute.[2][3][5] Yehudai-Reshef's 2006 research explored vaginal discharge as an untapped biomarker source for diseases like ovarian cancer and endometriosis, overcoming initial skepticism to identify 32 promising proteins, narrowed to 3-5 via AI.[3] Early milestones include Rambam MedTech support, winning MassChallenge Boston in an unspecified year, joining MindUP incubator in 2020, and Mayo Clinic accelerator participation.[3][4] By 2022-2023, it advanced to US trials at sites like Mayo Clinic and rebranded to Nevia Bio after seed funding.[4][8]
Gina Life rides the femtech boom, a growing market projected at billions per indication, fueled by AI/ML in diagnostics, post-pandemic at-home testing acceptance, and demands to close gender gaps in healthcare where ovarian cancer's late detection causes high mortality.[2][4][5] Timing aligns with women's health investments rising globally, democratizing access in developed and developing nations via non-invasive tech that eases hospital loads.[2][5] It influences the ecosystem by pioneering vaginal secretion analysis, inspiring fluid-based biomarker research, and partnering with institutions like Mayo Clinic and Technion, accelerating FDA/CMS paths and data collection for broader AI health tools.[3][4][8]
Gina Life (Nevia Bio) is poised for clinic-launched ovarian cancer tests by late 2023, followed by home-use versions, US commercialization post-trials, and pipeline expansions amid femtech growth.[4][5][8] Trends like AI diagnostics, self-testing normalization, and seed funding momentum will propel it, potentially capturing massive markets while evolving influence through global partnerships and revenue from data-driven tools. This positions it to save lives as envisioned—simply and early—transforming women's health from reactive to proactive.
Gina Life has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in August 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2023 | $3.0M Seed | Pitango Venture Capital |